. 2021 Sep 1;38(5):287–295. doi: 10.5152/balkanmedj.2021.20086
Content of this journal is licensed under a Table 5.
Patient Pathologic Characteristics in Relation to PD-L1 Expression
| Characteristic | Tumor Cell PD-L1 Expression >1% | Tumor Cell PD-L1 Expression <1% | P | Tumor-Infiltrating Immune Cell PD-L1 Expression >10% |
Tumor-Infiltrating Immune Cell PD-L1 Expression <10% |
P |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male | 49.7% (80) | 50.3% (81) | .673 | 27.3% (44) | 72.7% (117) | .241 |
| Female | 53.2% (25) | 46.8% (22) | 36.2% (17) | 63.8% (30) | ||
| Histology | ||||||
| Adenocarcinoma | 48.3% (70) | 51.7% (75) | .207 | 29.7% (43) | 70.3% (102) | .807 |
| Squamous Cell Carcinoma | 64.1% (25) | 35.9% (14) | 33.3% (13) | 66.7% (26) | ||
| NSCLC-NOS and Other | 41.6% (10) | 58.3% (14) | 20.8% (5) | 79.2% (19) | ||
| Molecular Signature | ||||||
| EGFR mutation | 44.4% (4) | 55.6% (5) | .964 | 33.3% (3) | 66.7% (6) | .680 |
| ALK rearrangement | 63.6% (7) | 36.3% (4) | .363 | 18.2% (2) | 81.8% (9) | .385 |
| ROS1 rearrangement | 50% (1) | 50% (1) | .966 | 0% (0) | 100% (2) | .376 |
EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma tyrosine kinase gene; ROS1, proto-oncogene tyrosine-protein kinase 1 ROS; PD-L1, programmed cell death protein ligand-1; NSCLC-NOS, non-small lung cancer-not otherwise specified.